Lung cancer (Amsterdam, Netherlands)

publication venue for

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. 2015
Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. 2011
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. 2010
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib.. 178. 2023
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.. 177. 2023
Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.. 176. 2022
The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma.. 174. 2022
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.. 166. 2021
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers.. 162. 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.. 161. 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.. 159. 2021
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.. 160. 2021
High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.. 157. 2021
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.. 155. 2021
Everolimus in the treatment of metastatic thymic epithelial tumors.. 149. 2020
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors.. 147. 2020
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.. 145. 2020
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study.. 142. 2020
Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.. 139. 2019
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.. 137. 2019
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.. 136. 2019
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.. 134. 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.. 133. 2019
Outcomes of Stage III NSCLC with occult primary vs. known primary lesions.. 127. 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.. 122. 2018
Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.. 119. 2018
What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. 118. 2018
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.. 116. 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.. 113. 2017
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.. 112. 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.. 108. 2017
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.. 108. 2017
Investigation of patterns of nodal metastases in BRAF mutant lung cancer.. 108. 2017
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).. 106. 2017
Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.. 106. 2017
Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.. 104. 2016
Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.. 101. 2016
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.. 101. 2016
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.. 99. 2016
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.. 99. 2016
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?. 90. 2015
Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma.. 89. 2015
Role of surgical resection for patients with limited disease-small cell lung cancer.. 88. 2015
Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. 86. 2014
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.. 86. 2014
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.. 84. 2014
Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China.. 84. 2014
High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.. 82. 2013
History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China.. 81. 2013
Reproducibility of the WHO classification of thymomas: practical implications.. 79. 2012
Beliefs and attitudes about lung cancer screening among smokers.. 77. 2012
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.. 77. 2012
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.. 76. 2011
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas.. 75. 2011
Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study.. 75. 2011
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis.. 74. 2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.. 74. 2011
Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.. 74. 2011
Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study.. 72. 2010
Health-related quality of life among early-stage, non-small cell, lung cancer survivors.. 71. 2010
Variation in vascular distribution in small lung cancers.. 68. 2009
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.. 68. 2009
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.. 67. 2009
Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications.. 64. 2008
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.. 63. 2008
Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study.. 62. 2008
Dietary factors, food contamination and lung cancer risk in Xuanwei, China.. 61. 2008
Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.. 60. 2007
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells.. 59. 2007
Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening.. 56. 2007
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer.. 55. 2006
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.. 55. 2006
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).. 50. 2005
Reduction of organ motion in lung tumors with respiratory gating.. 51. 2005
The effect of smoking status on survival following radiation therapy for non-small cell lung cancer.. 44. 2004
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.. 43. 2004
Expression of cancer/testis (CT) antigens in lung cancer.. 42. 2003
Lung cancer. Introduction.. 41 Suppl 1. 2003
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.. 39. 2003
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.. 38. 2002
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.. 32. 2001
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.. 33. 2001
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73].. 162. 2021
Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer.. 60 Suppl 2. 2008
Early lung cancer action project pathology protocol. 2003
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. 1996
Introduction.. 50S2. 2005
New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress.. 38 Suppl 4. 2002
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. 2019
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 2016
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. 2011
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. 2008
Ongoing and future trials of biologic therapies in lung cancer. 2003
Targeted therapy in non-small cell lung cancer. 2002
Chemotherapy for early stage non-small cell lung cancer. 2001
A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. 1997
Clinical features and current treatment of diffuse malignant pleural mesothelioma. 1995
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). 1995
New drugs in non-small cell lung cancer. An overview. 1995
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. 1995

VIVO Weill Cornell Medical College

Lung cancer (Amsterdam, Netherlands) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)